Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Status unconfirmed · Phase 2

Conditions studied: Breast Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in treating women who have metastatic breast cancer.

Key facts

Study ID

NCT00027989

Run by

Pharmatech Oncology

Starts

2001-12-01

Last updated by the study team

2013-12-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Montgomery Cancer Center — Montgomery, Alabama, United States
• California Cancer Medical Center — West Covina, California, United States
• Pharmatech Oncology — Denver, Colorado, United States
• Oncology-Hematology Associates, P.A. — Clinton, Maryland, United States
• South Carolina Oncology Associates — Columbia, South Carolina, United States
• South Carolina Oncology Associates — Columbia, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.